Drug
Brentuximab Vedotin clinical trials
Also written Adcetris, SGN-35 and cAC10-vcMMAE.
Keep track of what changes. Save the Brentuximab Vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
145 studies that test it; most in 2013 (22)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 4 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 9 |
| 2013 | 22 |
| 2014 | 12 |
| 2015 | 15 |
| 2016 | 12 |
| 2017 | 9 |
| 2018 | 14 |
| 2019 | 8 |
| 2020 | 6 |
| 2021 | 4 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 19
Who runs them
Industry 33 · Other 112
Seagen Inc. (17) · City of Hope Medical Center (8) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (7) · Takeda (7) · Massachusetts General Hospital (5) · Fondazione Italiana Linfomi - ETS (5) · Memorial Sloan Kettering Cancer Center (4)
Often tested with
Tested in the same studies.
Doxorubicin (13) · Dacarbazine (13) · Nivolumab (11) · Vinblastine (9) · Etoposide (9) · Cyclophosphamide (8) · Pembrolizumab (6) · Rituximab (6)
Related medicines
As reviewed, each with the page that says it.
- One of Immunotoxins source
Studies
Open first, then newest update. How each study uses Brentuximab Vedotin is read from its arms, and is right about nine times in ten.
Testing it · 145
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabRecruitingPhase 3National Cancer Institute (NCI)NCT05675410Written as Brentuximab Vedotin
- Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin LymphomaRecruitingPhase 2City of Hope Medical CenterNCT04561206Written as Brentuximab Vedotin
- Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsRecruitingPhase 2Emory UniversityNCT05039073Written as Brentuximab Vedotin
- Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaRecruitingEarly Phase 1New York Medical CollegeNCT03719105Written as Brentuximab Vedotin
- Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05357794Written as Brentuximab vedotin
- Brentuximab Vedotin in Early Stage Hodgkin LymphomaRecruitingPhase 3University College, LondonNCT04685616Written as Brentuximab vedotin
- Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular LymphomaRecruitingPhase 2University of California, DavisNCT04587687Written as Brentuximab Vedotin
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaRecruitingPhase 2Yale UniversityNCT05313243Written as Brentuximab vedotin
- Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCLRecruitingPhase 2New York Medical CollegeNCT07013565Written as Brentuximab vedotin (Adcetris)
- A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06377566Written as Brentuximab vedotin
- Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03587844Written as brentuximab vedotin
- A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in IndiaRecruitingPhase 4TakedaNCT06831370Written as Brentuximab Vedotin
- PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyRecruitingPhase 2M.D. Anderson Cancer CenterNCT04745949Written as Brentuximab Vedotin
- Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2Canadian Cancer Trials GroupNCT05180097Written as Brentuximab vedotin
- BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell LymphomasEnrolling by invitationPhase 3N.N. Petrov National Medical Research Center of OncologyNCT07258680Written as Brentuximab Vedotin (Bv)
- BrECADD Therapy in Stage 2 B-IV Hodgkin LymphomaRecruitingPhase 2University of MiamiNCT07002216Written as Brentuximab Vedotin
- Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant MaintenanceNot yet recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07178457Written as Brentuximab Vedotin (Bv)
- Treatment Strategy for Relapsed/Refractory Hodgkin LymphomaRecruitingPhase 2/3Hospital Regional de Alta Especialidad del BajioNCT05595447Written as Brentuximab Vedotin 50 MG [Adcetris]
- BREntuximab Vedotin in SEcond LIne Therapy BEfore TransplantRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT04378647Written as Induction with Brentuximab vedotin (BV)
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationPhase 2Beijing Children's HospitalNCT06201507Written as Brentuximab vedotin
See all 145 studies that test Brentuximab Vedotin →
Given in every arm · 23 — Brentuximab Vedotin is usual care beside what is tested
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentRecruitingPhase 2City of Hope Medical CenterNCT07275216Written as Brentuximab Vedotin
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingPhase 2Peking University First HospitalNCT07717580Written as Brentuximab Vedotin (Bv)
- Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07572123Written as Brentuximab Vedotin
- Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT AssessmentRecruitingPhase 2/3Children's Cancer Group, ChinaNCT06563245Written as Brentuximab Vedotin for Injection
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingPhase 4Xiuhua SunNCT06761911Written as Brentuximab Vedotin (Bv)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01896999Written as Brentuximab Vedotin
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaCompletedNot applicableMemorial Sloan Kettering Cancer CenterNCT01868451Written as Brentuximab vedotin (SGN-35)
- Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and AboveActive, not recruitingPhase 2University of VirginiaNCT05404945Written as Brentuximab vedotin
- Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaActive, not recruitingPhase 2University of WashingtonNCT01703949Written as Brentuximab Vedotin
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin LymphomaTerminatedPhase 2Seagen Inc.NCT03646123Written as brentuximab vedotin
- A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCompletedPhase 2Bristol-Myers SquibbNCT02927769Written as brentuximab vedotin
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedPhase 1Seagen Inc.NCT04254107Written as brentuximab vedotin
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedPhase 2Seagen Inc.NCT01716806Written as brentuximab vedotin
- A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnPhase 3National Cancer Institute (NCI)NCT05711628Written as Brentuximab Vedotin
- A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TerminatedPhase 3Bristol-Myers SquibbNCT03138499Written as Brentuximab vedotin
- Brentuximab for Newly Diagnosed Hodgkin DiseaseCompletedPhase 2Mitchell CairoNCT02398240Written as Brentuximab Vedotin
- Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)TerminatedPhase 1/2M.D. Anderson Cancer CenterNCT02096042Written as Brentuximab Vedotin
- Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma PatientsStatus unknownPhase 1/2New York Medical CollegeNCT02098512Written as Brentuximab Vedotin
- A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)WithdrawnPhase 2Yale UniversityNCT04138875Written as Brentuximab Vedotin
- Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin LymphomaCompletedPhase 2University of CologneNCT01569204Written as Brentuximab Vedotin
Showing 20 of 23.
As the comparator · 1 — what is tested is compared with Brentuximab Vedotin
Codes
What other systems call Brentuximab Vedotin · ClinicalTrials.gg INT006839
- MeSH (NLM) D000079963Brentuximab VedotinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7XL5ISS668BRENTUXIMAB VEDOTINConfirmed FDA, NLM, Wikidata
- RxNorm 1147320Confirmed FDA, Wikidata
- Wikidata Q422324brentuximab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66944Brentuximab VedotinOne source FDA
- DrugBank DB08870One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000079963 | Brentuximab Vedotin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7XL5ISS668 | BRENTUXIMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1147320 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422324 | brentuximab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66944 | Brentuximab Vedotin | One source FDA |
| DrugBank | DB08870 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.